Elevation Oncology, Inc.
ELEV · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $29 | $25 | $79 | $24 |
| G&A Expenses | $16 | $15 | $16 | $8 |
| SG&A Expenses | $16 | $15 | $16 | $8 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $5 | $0 | $0 |
| Operating Expenses | $45 | $45 | $95 | $32 |
| Operating Income | -$45 | -$45 | -$95 | -$32 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | -$0 | -$1 | $0 |
| Pre-Tax Income | -$44 | -$46 | -$95 | -$32 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$44 | -$46 | -$95 | -$32 |
| % Margin | – | – | – | – |
| EPS | -0.78 | -1.34 | -4.09 | -1.38 |
| % Growth | 41.8% | 67.2% | -196.4% | – |
| EPS Diluted | -0.78 | -1.34 | -4.09 | -1.38 |
| Weighted Avg Shares Out | 57 | 34 | 23 | 23 |
| Weighted Avg Shares Out Dil | 57 | 34 | 23 | 23 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $4 | $0 | $0 |
| Interest Expense | $4 | $4 | $0 | $0 |
| Depreciation & Amortization | -$1 | $0 | $0 | $0 |
| EBITDA | -$45 | -$41 | -$95 | -$32 |
| % Margin | – | – | – | – |